Cipla launches ‘Yurpeak’

10 Dec 2025 Evaluate

Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) - two of the country’s most pressing health challenges. The company has the rights to distribute and promote Yurpeak - the second brand of Lilly’s tirzepatide in India, after Lilly received DCGI approval. 

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Yurpeak will be available on prescription in the KwikPen device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1507.95 7.85 (0.52%)
02-Jan-2026 10:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1725.95
Dr. Reddys Lab 1245.00
Cipla 1507.95
Zydus Lifesciences 913.85
Lupin 2105.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×